Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Diagnostic Techniques | 4 | 2020 | 69 | 1.390 |
Why?
|
| Microbiological Techniques | 5 | 2019 | 24 | 1.080 |
Why?
|
| Bacteria | 4 | 2017 | 447 | 0.970 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 73 | 0.960 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 316 | 0.940 |
Why?
|
| Bacteremia | 2 | 2014 | 99 | 0.940 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 293 | 0.930 |
Why?
|
| Betacoronavirus | 3 | 2020 | 258 | 0.890 |
Why?
|
| Mycoplasma genitalium | 1 | 2022 | 2 | 0.870 |
Why?
|
| Mycoplasma Infections | 1 | 2022 | 8 | 0.860 |
Why?
|
| Gonorrhea | 1 | 2022 | 18 | 0.860 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 25 | 0.850 |
Why?
|
| Mycobacterium chelonae | 1 | 2021 | 4 | 0.810 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 24 | 0.790 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 91 | 0.770 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 80 | 0.730 |
Why?
|
| Immunoglobulin G | 3 | 2021 | 456 | 0.720 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 376 | 0.690 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 192 | 0.670 |
Why?
|
| Bacteriological Techniques | 2 | 2019 | 39 | 0.670 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 186 | 0.670 |
Why?
|
| Blood | 2 | 2017 | 69 | 0.660 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.640 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2014 | 74 | 0.640 |
Why?
|
| Influenza, Human | 2 | 2018 | 329 | 0.630 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2017 | 23 | 0.620 |
Why?
|
| Actinomyces | 1 | 2015 | 5 | 0.540 |
Why?
|
| Earache | 1 | 2015 | 4 | 0.530 |
Why?
|
| Actinomycosis | 1 | 2015 | 12 | 0.530 |
Why?
|
| Maxillary Sinusitis | 1 | 2015 | 16 | 0.530 |
Why?
|
| Neisseria meningitidis, Serogroup Y | 1 | 2014 | 2 | 0.520 |
Why?
|
| Arthritis, Infectious | 1 | 2014 | 16 | 0.510 |
Why?
|
| Sensitivity and Specificity | 8 | 2022 | 1991 | 0.500 |
Why?
|
| Specimen Handling | 1 | 2014 | 98 | 0.480 |
Why?
|
| Knee Joint | 1 | 2014 | 168 | 0.470 |
Why?
|
| Adenoviridae Infections | 1 | 2012 | 15 | 0.440 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 40 | 0.400 |
Why?
|
| Serologic Tests | 2 | 2020 | 41 | 0.380 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 140 | 0.360 |
Why?
|
| Nasopharynx | 2 | 2020 | 47 | 0.340 |
Why?
|
| Humans | 29 | 2022 | 86643 | 0.290 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 105 | 0.280 |
Why?
|
| Automation, Laboratory | 2 | 2020 | 10 | 0.230 |
Why?
|
| Blood Gas Analysis | 2 | 2020 | 37 | 0.230 |
Why?
|
| Microscopy | 2 | 2014 | 87 | 0.230 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2020 | 36 | 0.220 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 14 | 0.220 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2022 | 16 | 0.220 |
Why?
|
| Prospective Studies | 2 | 2022 | 4213 | 0.200 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 34 | 0.200 |
Why?
|
| Gastritis | 1 | 2021 | 32 | 0.190 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 35 | 0.190 |
Why?
|
| Syringes | 1 | 2020 | 13 | 0.190 |
Why?
|
| Plasma Cells | 1 | 2021 | 80 | 0.190 |
Why?
|
| Child, Preschool | 3 | 2021 | 3612 | 0.190 |
Why?
|
| Adult | 7 | 2021 | 25648 | 0.190 |
Why?
|
| Blood Specimen Collection | 1 | 2020 | 27 | 0.190 |
Why?
|
| Stomach | 1 | 2021 | 108 | 0.190 |
Why?
|
| Biopsy | 2 | 2021 | 1163 | 0.190 |
Why?
|
| Time Factors | 5 | 2017 | 5210 | 0.190 |
Why?
|
| Cross Reactions | 4 | 2021 | 106 | 0.180 |
Why?
|
| Pathology, Surgical | 1 | 2019 | 12 | 0.180 |
Why?
|
| Male | 11 | 2022 | 40965 | 0.180 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 160 | 0.180 |
Why?
|
| Nasal Mucosa | 1 | 2020 | 186 | 0.180 |
Why?
|
| Chicago | 3 | 2020 | 1379 | 0.180 |
Why?
|
| Catheters | 1 | 2020 | 74 | 0.180 |
Why?
|
| Pharyngitis | 1 | 2019 | 16 | 0.180 |
Why?
|
| Streptococcus pyogenes | 1 | 2019 | 34 | 0.180 |
Why?
|
| Autopsy | 1 | 2019 | 116 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 143 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 57 | 0.170 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.170 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 298 | 0.170 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2018 | 13 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 21 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 125 | 0.160 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2018 | 80 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2018 | 65 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 6 | 0.160 |
Why?
|
| Influenza B virus | 1 | 2017 | 29 | 0.160 |
Why?
|
| Lymphotoxin alpha1, beta2 Heterotrimer | 1 | 2017 | 4 | 0.150 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2017 | 29 | 0.150 |
Why?
|
| Workflow | 1 | 2017 | 77 | 0.150 |
Why?
|
| Fungi | 1 | 2017 | 65 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 142 | 0.150 |
Why?
|
| Pandemics | 2 | 2020 | 740 | 0.150 |
Why?
|
| Influenza A virus | 1 | 2017 | 169 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2020 | 373 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 102 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 273 | 0.140 |
Why?
|
| Seminal Vesicles | 1 | 2016 | 39 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 144 | 0.130 |
Why?
|
| Maxillary Sinus | 1 | 2015 | 26 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 464 | 0.130 |
Why?
|
| Middle Aged | 7 | 2021 | 25028 | 0.130 |
Why?
|
| Oseltamivir | 1 | 2015 | 20 | 0.130 |
Why?
|
| Histocytochemistry | 2 | 2012 | 130 | 0.130 |
Why?
|
| Oxygen | 1 | 2020 | 726 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2015 | 97 | 0.120 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.120 |
Why?
|
| Sepsis | 1 | 2017 | 306 | 0.120 |
Why?
|
| Yeasts | 1 | 2013 | 49 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2017 | 409 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6509 | 0.120 |
Why?
|
| Mycoses | 1 | 2013 | 46 | 0.120 |
Why?
|
| Temperature | 1 | 2014 | 396 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 746 | 0.110 |
Why?
|
| Child | 4 | 2021 | 6927 | 0.110 |
Why?
|
| Family Health | 1 | 2012 | 162 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2013 | 182 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 293 | 0.100 |
Why?
|
| Microbiota | 1 | 2017 | 381 | 0.100 |
Why?
|
| DNA, Bacterial | 3 | 2019 | 236 | 0.100 |
Why?
|
| Female | 8 | 2021 | 44532 | 0.100 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2011 | 4 | 0.100 |
Why?
|
| Pseudomonas | 1 | 2011 | 51 | 0.100 |
Why?
|
| Infant | 1 | 2017 | 3046 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2015 | 510 | 0.100 |
Why?
|
| Aged | 5 | 2021 | 18415 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 927 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 95 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 5976 | 0.090 |
Why?
|
| Antigens, Viral | 2 | 2021 | 143 | 0.090 |
Why?
|
| Tinea Capitis | 1 | 2009 | 2 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2020 | 216 | 0.090 |
Why?
|
| Lung | 2 | 2012 | 1170 | 0.090 |
Why?
|
| Adolescent | 2 | 2021 | 8981 | 0.080 |
Why?
|
| Microsporum | 1 | 2007 | 1 | 0.080 |
Why?
|
| Tinea Favosa | 1 | 2007 | 1 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2019 | 39 | 0.080 |
Why?
|
| Multiplex Polymerase Chain Reaction | 2 | 2018 | 33 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1673 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1753 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2705 | 0.060 |
Why?
|
| Gastroscopy | 1 | 2021 | 23 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 67 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 154 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 67 | 0.050 |
Why?
|
| Epitopes | 1 | 2021 | 255 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 112 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2019 | 48 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 254 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 45 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 24 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 493 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 134 | 0.040 |
Why?
|
| Eggs | 1 | 2018 | 12 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Ferrets | 1 | 2018 | 47 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 41 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2018 | 74 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 94 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 379 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 103 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 297 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 194 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 89 | 0.040 |
Why?
|
| Seasons | 1 | 2018 | 223 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 348 | 0.040 |
Why?
|
| United States | 2 | 2019 | 6672 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2021 | 8489 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 724 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 306 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 456 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1718 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 131 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 1137 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1924 | 0.030 |
Why?
|
| Inflammation | 1 | 2017 | 920 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2767 | 0.030 |
Why?
|
| Mycobacterium avium Complex | 1 | 2011 | 6 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 28 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 44 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2011 | 241 | 0.020 |
Why?
|
| Griseofulvin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Trichophyton | 1 | 2009 | 1 | 0.020 |
Why?
|
| Africa, Western | 1 | 2009 | 10 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2009 | 25 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1169 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2009 | 117 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 26582 | 0.020 |
Why?
|
| HIV Infections | 1 | 2016 | 772 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 853 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 3968 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3030 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1721 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 864 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 11352 | 0.010 |
Why?
|